Pacific Biosciences of California (PACB) closed at $2.90, up 2.47 percent on Oct. 29, 2026, defying a broader selloff that sent the S&P 500 down 0.31 percent, the Dow down 0.25 percent, and the Nasdaq down 1.38 percent.
The outperformance is striking: PACB has gained 19.41 percent over the past month, crushing both the Medical sector's 2.58 percent advance and the S&P 500's 0.87 percent gain. The rally arrives ahead of third-quarter earnings due Nov. 4, when the genetic analysis technology maker is expected to report a loss of $0.13 per share on revenue of $37.86 million—down 1.52 percent year-over-year.
Full-year guidance tells a more complex story. Zacks Consensus Estimates project full-year earnings of negative $0.43 per share, an 18.87 percent improvement from last year's loss, against revenue of $156.1 million, down 2.44 percent. The EPS estimate for Q3 represents an 8.33 percent deterioration versus the year-ago quarter.
The Zacks Rank holds PACB at #3 (Hold). Analyst estimates have remained stagnant over the past month. The Medical-Instruments industry trades at a Zacks Industry Rank of 148, placing it in the bottom 40 percent of 250+ measured sectors.
